Skip to content
Demo
Creator Hubs›Therapanacea

Therapanacea

Therapanacea logo

AI-powered precision oncology

Therapanacea is an AI company focused on transforming cancer care through science-driven clinical solutions. Their flagship platform, ART-Plan™, automates end-to-end workflows for adaptive radiotherapy: segmentation, treatment planning, and adaptive monitoring. Built in close collaboration with leading global cancer centers, Therapanacea's innovations deliver augmented clinical intelligence to support precision oncology for patients worldwide.

2 episodesVisit website ↗
Channel Brief·Therapanacea · 2 episodes
Updated Sep 11, 2026

AI Adoption in Cancer Care Requires Gradual, Human-Led Implementation

Two oncology leaders demonstrate how AI tools streamline treatment planning when deployed with clinical oversight and staff confidence-building, not as replacements for expertise.

TheraPanacea's channel argues that AI in oncology succeeds only when embedded into existing workflows through deliberate, people-first adoption—not technology-first rollout. Both featured practitioners credit gradual implementation, human validation, and clear clinical wins (fewer CT scans, precision contouring) as the evidence that AI augments rather than displaces physician judgment.

Drawn from Dr. Sotirios Stathakis: A TheraPanacea Custome… and 1 more →

“AI applications show significant advancement potential, but require consistent human leadership and oversight.”

Dr. Dana Rosencranz, Chief Medical Physicist, Texas Oncology

By the numbers

40-45%

of cases using Annotate tool for head, neck, abdominal procedures

40-45%

Annotate tool adoption rate in head, neck, abdominal procedures

5 years

Dr. Rosencranz's tenure as breast cancer survivor

What the channel argues

InsightMary Bird Perkins reduced CT scan dependency via MRI-only workflow for prostate and bladder cancer.→
DataAnnotate tool adoption reached 40-45% usage rate in head, neck, and abdominal procedures.→
InsightSuccessful AI implementation begins with control cases, builds team confidence, then expands gradually.→
InsightDr. Rosencranz combines five-year cancer survivor perspective with Chief Medical Physicist role to drive personalized care.→
InsightTexas Oncology serves rural demographics where travel barriers exist while maintaining cutting-edge technology access.→

What you'll learn

•How MRI-only imaging reduces scan burden and operational cost for specific cancer types at scale.
•Why phased adoption starting with control cases builds clinician trust before enterprise-wide AI rollout.
•How survivor-informed leadership shapes empathy-driven AI implementation in oncology settings.
•What percentage adoption rates of auto-contouring tools look like in real multi-site cancer networks.

What to do about it

→Start AI implementation with control cases and measure staff adoption rate before expanding to all departments.
→Pair clinical leadership with survivor-informed perspectives when designing patient-facing AI tools and workflows.
→Audit imaging protocols to identify cancer types where MRI-only workflows can reduce unnecessary CT scans and costs.

Who and what shows up

Dr. Sotirios Stathakis

Chief of Physics, Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana

Pioneered TheraPanacea adoption at Louisiana's largest cancer facility, demonstrating phased AI implementation strategy and MRI-only workflow benefits.

Dr. Dana Rosencranz

Chief Medical Physicist, Texas Oncology

Five-year breast cancer survivor who emphasizes AI requires human leadership oversight; drives patient empathy and rural access advocacy.

Mary Bird Perkins Cancer Center

Louisiana's largest cancer treatment facility

Adopted TheraPanacea tools starting in 2021, demonstrating real-world 40-45% Annotate tool adoption and MRI-only workflow success.

Texas Oncology

Multi-site cancer care network

Serves rural and urban demographics while integrating AI tools, balancing technology advancement with patient accessibility.

Questions this channel answers

Q

How should a cancer center roll out AI tools without disrupting clinician workflow?

Begin with control cases, measure results, build team confidence, then expand gradually to ensure smooth adoption and staff acceptance.

Dr. Sotirios Stathakis: A TheraPanacea Customer Intervie… →
Q

What role does human oversight play in AI-powered cancer treatment planning?

AI applications show significant advancement potential, but require consistent human leadership and oversight to remain effective and trustworthy.

Dr. Dana Rosencranz - Cancer Survivor and Chief Medical … →
Q

What imaging workflows can AI help optimize for specific cancer types?

MRI-only workflow adoption via MRI Box reduces the need for CT scans, particularly for prostate and bladder cancer treatment.

Dr. Sotirios Stathakis: A TheraPanacea Customer Intervie… →
Topics:AI auto-contouring and treatment planningMRI-only workflow adoptionCancer center operational efficiencyClinical staff adoption strategy
Themes:Human oversight and clinical judgment remain essential in AI-augmented medicinePhased adoption builds staff confidence and operational stability over speedSurvivor-informed leadership deepens empathy in technology-driven cancer care

Industry context

Healthcare organizations are integrating AI into clinical workflows, with emphasis on practical deployment approaches that maintain clinician oversight and operational stability.

Want a show like this for your brand?

MarketScale produces and distributes branded shows like Therapanacea for B2B companies.

Book a Demo →